Global Clinical Trial Imaging Market – Industry Trends and Forecast to 2031

Clinical Trial Imaging Market Analysis and Size

Efficacy assessment in the clinical trial imaging market involves using various imaging modalities such as MRI, CT scans, and PET scans to quantify treatment response and therapeutic outcomes. It visualizes changes in disease biomarkers, tumor size, or physiological parameters over time, imaging enables researchers to objectively evaluate the effectiveness of investigational drugs or therapies. This application allows for the identification of promising treatments and the optimization of dosage regimens.

Global clinical trial imaging market size was valued at USD 1.14 billion in 2023 and is projected to reach USD 2.13 billion by 2031, with a CAGR of 8.1% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Market Definition

Clinical trial imaging involves the use of various imaging techniques, such as MRI, CT scans, X-rays, and PET scans, to evaluate the efficacy and safety of medical interventions in clinical trials. These imaging modalities help researchers visualize internal structures and physiological processes, allowing for the assessment of treatment response, disease progression, and adverse effects. It provides objective data, clinical trial imaging enhances the understanding of a drug or therapy's effects, aiding in decision-making processes and regulatory approvals.

Clinical Trial Imaging Market Dynamics

Drivers

• Rise in Healthcare Expenditure Results in Improved Infrastructure

Increased healthcare spending indicates a greater investment in medical research and development, including clinical trials utilizing imaging technologies. With more resources allocated to healthcare, there is a heightened demand for innovative diagnostic and therapeutic solutions, prompting the expansion of clinical trials incorporating imaging modalities. Moreover, higher healthcare expenditure often correlates with improved infrastructure and access to advanced imaging facilities, facilitating the conduct of imaging-intensive research. This trend fosters collaborations between pharmaceutical companies, contract research organizations (CROs), and imaging centers, driving the growth of the clinical trial imaging market as a crucial component of modern healthcare innovation.

The 4.6% growth in U.S. healthcare expenditure reported by the National Health Expenditure Accounts in 2019, totaling USD 3.80 trillion, signifies a significant investment in medical research and development, including clinical trials with imaging technologies. This increased spending reflects a heightened demand for innovative diagnostic and therapeutic solutions, fostering collaborations between pharmaceutical companies, contract research organizations (CROs), and imaging centers to drive growth in the clinical trial imaging market as a vital component of modern healthcare innovation.

• Increasing Technological Advancement Enhances Capabilities in Medical Imaging Modalities

The development of advanced imaging techniques, such as functional MRI (fMRI), diffusion-weighted imaging (DWI), and molecular imaging, enables researchers to obtain more detailed and precise information about biological processes and disease states. Moreover, improvements in imaging hardware and software, including higher resolution scanners, faster image acquisition, and better image analysis algorithms, contribute to enhanced image quality, increased efficiency, and improved data interpretation in clinical trials. These technological advancements not only enable more accurate efficacy assessments and safety evaluations but also facilitate the discovery of novel imaging biomarkers, driving further adoption of imaging-based approaches in clinical research and drug development.

Opportunities

• Growing Strategic Initiatives by Market Players Enhances Product Offerings

Strategic initiatives include partnerships, collaborations, acquisitions, and investments aimed at expanding technological capabilities, enhancing service offerings, and improving market presence. It leverages strategic alliances with pharmaceutical companies, research organizations, and regulatory bodies, market players can access new opportunities for innovation and market penetration. Furthermore, investments in research and development enable the development of advanced imaging technologies and solutions tailored to the evolving needs of clinical trials.

In February 2020, ICON plc acquired MedPass International, bolstering its European presence and expanding its medical device and diagnostic research services. This acquisition allowed ICON to discover MedPass's expertise in regulatory consultancy and reimbursement, strengthening its capabilities to support clients in navigating complex European regulatory environments and accelerating the development of medical devices and diagnostics.

• Increasing Number of Contract Research Organizations (CROs) Leads to the Adoption of Imaging Technologies

CROs specialize in providing outsourced services for clinical research, including imaging-related tasks such as protocol development, image acquisition, analysis, and interpretation. As pharmaceutical and biotechnology companies increasingly rely on CROs to conduct clinical trials, the demand for imaging services offered by these organizations grows substantially. CROs offer expertise, efficiency, and cost-effectiveness in managing imaging aspects of clinical trials, thereby driving the adoption of imaging technologies and enhancing the overall efficiency of the drug development process.

Restraints/Challenges

• High Potential Risk of Radiation Exposure limits the Adoption of Clinical Trial Imaging

High doses of ionizing radiation from modalities such as CT scans and PET scans pose health risks, including an increased such aslilihood of developing radiation-induced diseases such as cancer. Concerns regarding cumulative radiation exposure over the course of multiple imaging sessions further contribute to this restraint, particularly in longitudinal or repeat imaging studies.

For Instance,

• The Radiological Society of America (RSNA) reports that 1% to 2% of all cancers in the U.S. are attributed to CT scans, while the American Cancer Society links CT scans and X-rays to increased risks of breast cancer, brain cancer, and other malignancies

Time Consuming Professional Training Limits the Growth of POCT

Adequate training is essential for healthcare personnel to effectively operate POCT devices, interpret results accurately, and ensure patient safety. However, providing comprehensive training programs can be resource-intensive and time-consuming for healthcare facilities, particularly in settings with limited access to education and training resources. Insufficient training may result in errors in testing procedures, misinterpretation of results, and compromised patient care.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In November 2021, ERT and Bioclinica merged, forming Clario. This consolidation led to increased sales and the distribution of clinical imaging software and services
• In January 2022, Clario collaborated with XingImaging in China to facilitate PET imaging clinical trials for testing novel therapeutics. The collaboration aims to leverage joint resources and neuroscience expertise to expedite clinical trial start-up and drug discovery
• In March 2022, Fujifilm India launched a new range of medical imaging equipment including CT, MRI, X-ray, AI, endoscopy, and ultrasound systems. The portfolio includes the Scenaria View, Supria series, The Echelon Smart, and Arietta series
• In May 2022, Bruker launched innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets at the ISMRM 2022 conference. These magnets enhance their preclinical MRI systems portfolio, catering to advanced research needs

Clinical Trial Imaging Market Scope

The market is segmented into five segments based on product and services, modality, application, end user and distributor. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

• Services
• Software

Modality

• Computed Tomography
• Magnetic Resonance Imaging
• Echocardiography
• Nuclear Medicine
• Positron Emission Tomography
• X-Ray
• Ultrasound
• Optical Coherence Tomography
• Others

Application

• Oncology
•  Neurology
•  Cardiology
•  Endocrinology
•  Dermatology
•  Hematology
•  Others

End User

• Contract Research Organizations
• Pharmaceutical and Biotechnology Companies
• Medical Device Manufacturers
• Academic and Government Research Institutes
• Others

Distributor

• Direct Sales
•  Tender Sales

 Clinical Trial Imaging Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by regions, product and services, modality, application, end user and distributor as referenced above.

The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, South Africa, Saudi Arabia, rest of Middle East and Africa, Brazil and rest of South America.

In North America, U.S. dominates the market due to its superior reimbursement policies compared to other physician providers. This favorable reimbursement environment incentivizes investment in research and development (R&D), leading to continuous advancements in imaging modalities. Additionally, both the U.S. and Canada have experienced a rise in the number of contract research organizations (CROs) dedicated to improving imaging technologies, further contributing to the region's leadership in this field.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Clinical Trial Imaging Market Analysis

The market competitive landscape provides details on the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, the global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth and application dominance. The above data points provided are only related to the companies' focus related to the global clinical trial imaging market.

Some of the major players operating in the market are:

• Navitas Life Sciences  (U.S.)
• Resonance Health Ltd.  (Australia)
• BioTelemetry, a Philips Company.(U.S.)
• IXICO plc  (U.K.)
• ICON plc  (Ireland)
• Image Core Lab  (U.S.)
• anagram 4 clinical trials  (India)
• Quotient Sciences  (U.K.)
• Radiant Sage LLC  (U.S.)
• WORLDCARE CLINICAL  (U.S.)
• Clario  (U.S.)
• Parexel International Corporation  (U.S.)
• Median Technologies  (France)
• Perspectum  (U.K.)
• Calyx  (U.S.)
• Invicro LLC  (U.S.)

SKU-15105